Results 171 to 180 of about 27,058 (217)

Risk–Benefit Analysis of Primary Prophylaxis Against Pneumocystis Jirovecii Pneumonia in Patients With Rheumatic Diseases Receiving Rituximab

Arthritis & Rheumatology, 2023
To identify a specific population of patients with rheumatic diseases receiving rituximab treatment for whom the benefit from primary prophylaxis against Pneumocystis jirovecii pneumonia (PJP) outweighs the risk of adverse events (AEs).
Jun Won Park, J. Curtis, S. Choi, Min Jung Kim, Y. Ha, E. Kang, Y. Lee, Eun Bong Lee   +7 more
semanticscholar   +1 more source

High prevalence and mortality of Pneumocystis jirovecii pneumonia in anti-MDA5 antibody-positive dermatomyositis.

Rheumatology, 2023
OBJECTIVES To identify potential risk factors and prognostic factors of Pneumocystis jirovecii pneumonia (PJP) infection in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis (anti-MDA5+ DM) patients, and to evaluate the ...
Xixia Chen, X. Shu, Linrong He, Hanbo Yang, Xin Lu, Guochun Wang, Y. Ge   +6 more
semanticscholar   +1 more source

Granulomatous Pneumocystis Jirovecii Pneumonia

C69. FUNGAL INFECTION CHALLENGES
M. Agustin, M. Yamamoto
semanticscholar   +2 more sources

Purine antimetabolites associated Pneumocystis jirovecii pneumonia

Pharmacoepidemiology and Drug Safety, 2023
To detect the possible safety signal of purine antimetabolites associated with Pneumocystis jirovecii pneumonia through disproportionality analysis in the FDA Adverse Event Reporting System (FAERS) Database.
Lipin Lukose, Pawar Mansi Shantaram, Alan Raj, G. Nair, Aina M Shaju, Subeesh K Viswam   +5 more
semanticscholar   +1 more source

Adjunctive corticosteroids in non-AIDS patients with severe Pneumocystis jirovecii pneumonia (PIC): a multicentre, double-blind, randomised controlled trial.

The Lancet Respiratory Medicine
BACKGROUND Pneumocystis jirovecii pneumonia in HIV-negative immunocompromised patients has a hospital mortality rate of 30-50%. Adjunctive corticosteroids improve outcomes of P jirovecii pneumonia in HIV-positive patients.
V. Lemiale, M. Resche-Rigon, Y. Zerbib, D. Mokart, N. de Prost, F. Wallet, Pierre Perez, A. Kouatchet, Laurent Argaud, M. Decavèle, Édéric Pène, A. Séguin, B. Mégarbane, Laure Calvet, Muriel Picard, G. Rigault, É. Mariotte, L. Bouadma, I. Théodose, F. Tamion, K. Klouche, G. Colin, M. Nyunga, A. Moreau, Élie Azoulay   +24 more
semanticscholar   +1 more source

An Observational Analysis of a Large Cohort of Pneumocystis jirovecii Pneumonia

Open Forum Infectious Diseases
Background Pneumocystis jirovecii pneumonia (PCP) is increasingly seen in patients who are non-HIV immunocompromised hosts, yet modern risk factors and outcomes are poorly recognized and defined.
A. Pulsipher, H. Vikram, M. Gotway, Rodrigo Cartin-Ceba, Kyle J. Henry, Alec Johnson, Ryan R Gassner, Kevin Zhou, D. Green, Emily R Thompson, Andrew H. Limper, Ayan Sen, Augustine S. Lee, K. Ham   +13 more
semanticscholar   +1 more source

Pneumocystis jirovecii Pneumonia

2020
The life cycle of Pneumocystis jirovecii is complicated. It tries to find a damaged immune system to replicate, leading to life-threatening complications. With the treatment of immunosuppressive drugs, Pneumocystis jirovecii pneumonia has become a common opportunistic infection in non-AIDS populations. A CD4+ lymphocyte count of
Jing Feng, Bo Wu, Erlie Jiang, Wen Li, Chen Meng   +4 more
openaire   +1 more source

Diagnostic values of BALF metagenomic next-generation sequencing, BALF real-time PCR and serum BDG for Pneumocystis jirovecii pneumonia in HIV-infected patients

Frontiers in Microbiology
Introduction This study aimed to assess the diagnostic values of bronchoalveolar lavage fluid (BALF) real-time polymerase chain reaction (PCR) and BALF metagenomic next-generation sequencing (mNGS) for Pneumocystis jirovecii pneumonia (PJP) in patients ...
Qianhui Chen, Xiaoping Chen, Pingzheng Mo, Liangjun Chen, Qian Du, Wenjia Hu, Q. Jiang, Zhongwei Zhang, Yongxi Zhang, Qinglian Guo, Yong Xiong, Liping Deng   +11 more
semanticscholar   +1 more source

Pathophysiological mechanism of non-HIV Pneumocystis jirovecii pneumonia.

Respiratory Investigation, 2022
While Pneumocystis jirovecii pneumonia (PCP) can occur in immunocompromised patients with HIV infection, the prognosis of non-HIV PCP is still poor, showing a high mortality rate of 30%-75%.
N. Asai, S. Motojima, Y. Ohkuni, R. Matsunuma, Tamao Nakashita, Norihiro Kaneko, H. Mikamo   +6 more
semanticscholar   +1 more source

Non-invasive diagnosis of Pneumocystis jirovecii pneumonia: A systematic review and meta-analysis.

Clinical Microbiology and Infection, 2021
BACKGROUND Pneumocystis jirovecii pneumonia (PCP) is an opportunistic infection commonly affecting immunocompromised people. Diagnosis usually requires invasive techniques to obtain respiratory specimens.
J. Senécal, E. Smyth, O. Del Corpo, J. Hsu, A. Amar-Zifkin, A. Bergeron, M. Cheng, G. Butler-Laporte, E. McDonald, T. Lee   +9 more
semanticscholar   +1 more source